Ipilimumab Feasible for Patients Who Relapse After Stem-cell Transplantation – Cancer Therapy Advisor
|
Ipilimumab Feasible for Patients Who Relapse After Stem–cell Transplantation
Cancer Therapy Advisor Administration of the anti-CTLA-4 antibody ipilimumab is feasible for patients with recurrent hematologic malignancies. Despite the occurrence of immune-mediate toxic effects and graft-versus-host disease (GVHD), administration of the anti-cytotoxic … |
